Skip to main content
. 2016 Jun 13;29(6):832–845. doi: 10.1016/j.ccell.2016.04.014

Figure 6.

Figure 6

Therapeutic Targeting of CXCR2 Inhibits Metastasis and Prolongs Survival in KPC Mice

(A) Boxplot showing circulating neutrophils in CXCR2 SM-treated mice (n = 4). p Values, Mann-Whitney U test.

(B) Kaplan-Meier survival analysis of KPC mice treated from 10 weeks of age with vehicle (n = 11), gemcitabine (n = 14), CXCR2 SM (n = 15), or CXCR2 SM + gemcitabine (n = 12). p Values, log rank test.

(C) Table comparing incidence of metastases in KPC mice treated as indicated. p Values, chi-square test.

(D–F) H&E staining and IHC for MPO, F4/80, CD3, and tenascin C (TNC) in tumors in response to (D) vehicle, (E) CXCR2 SM, and (F) CXCR2 SM + gemcitabine. See also Figure S5 and Table S1.